股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2025年10月8日 第 1 頁 共 11 頁 v 1.1.1 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分類 ...

目錄 | 釋義 | 2 | | --- | --- | | 技術詞彙 | 5 | | 公司資料 | 6 | | 財務概要 | 8 | | 主席報告 | 9 | | 管理層討論及分析 | 10 | | 企業管治及其他資料 | 29 | | 未經審核綜合損益及其他全面收益表 | 40 | | 未經審核綜合財務狀況表 | 42 | | 未經審核綜合權益變動表 | 44 | | 未經審核綜合現金流量表 | 46 | | 未經審核中期財務報告附註 | 47 | 釋義 於本報告內，除文義另有所指外，下列詞彙具有以下涵義。該等詞彙及其定義未必與任何業內標準定義相符，亦未必 可直接與其他在本公司相同行業內經營的公司所採用的同類詞彙比較。 | 「2022年H股激勵計劃」 | 指 | 本公司於2022年6月24日採納及批准的H股獎勵計劃，其主要條款載於日期 | | --- | --- | --- | | | | 為2022年5月26日的通函 | | 「A股」 | 指 | 本公司已發行每股面值人民幣1.00元的普通股，將以人民幣認購或入賬列為 | | | | 已繳，並於上海證券交易所上市買賣 | | 「聯繫人」 | 指 | 具有上 ...

JOINN Laboratories (China) Co., Ltd. 北京昭衍新藥研究中心股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code 股份代號：6127） NOTIFICATION LETTER 通知信函 Dear Non-Registered Shareholders, JOINN Laboratories (China) Co., Ltd. (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's websit ...

If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company's H share registrar in Hong Kong, Tricor Investor Services Limited ("H Share Registrar") at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mail ...

目錄 | 釋義 | 2 | | --- | --- | | 技術詞彙 | 5 | | 公司資料 | 6 | | 財務概要 | 8 | | 主席報告 | 9 | | 管理層討論及分析 | 10 | | 企業管治及其他資料 | 29 | | 未經審核綜合損益及其他全面收益表 | 40 | | 未經審核綜合財務狀況表 | 42 | | 未經審核綜合權益變動表 | 44 | | 未經審核綜合現金流量表 | 46 | | 未經審核中期財務報告附註 | 47 | 釋義 於本報告內，除文義另有所指外，下列詞彙具有以下涵義。該等詞彙及其定義未必與任何業內標準定義相符，亦未必 可直接與其他在本公司相同行業內經營的公司所採用的同類詞彙比較。 | 「2022年H股激勵計劃」 | 指 | 本公司於2022年6月24日採納及批准的H股獎勵計劃，其主要條款載於日期 | | --- | --- | --- | | | | 為2022年5月26日的通函 | | 「A股」 | 指 | 本公司已發行每股面值人民幣1.00元的普通股，將以人民幣認購或入賬列為 | | | | 已繳，並於上海證券交易所上市買賣 | | 「聯繫人」 | 指 | 具有上 ...

Core Viewpoint - The announcement of a 100% tariff on patented and branded drugs by the Trump administration starting October 1, 2025, aims to pressure pharmaceutical companies to relocate production to the U.S. [1] Market Reaction - Global pharmaceutical stocks, including Pfizer and Merck, experienced declines of over 2% in the U.S. market, while related stocks in A-shares and Hong Kong also fell significantly, impacting companies like Kanglong Chemical and Kylin Pharmaceutical [3] Policy Background - The tariff policy is not sudden; it has been hinted at since April, with escalating threats of high tariffs on imported drugs. Economists warn that such high tariffs could disrupt supply chains and potentially increase drug prices for U.S. consumers [4] Impact on Chinese Pharmaceutical Companies - Chinese innovative pharmaceutical companies face both challenges and opportunities. Short-term market volatility is expected, but the established global competitiveness of Chinese firms may allow them to adapt by accelerating overseas production to avoid tariffs [5] Industry Outlook - The fundamental drivers of innovative drug development remain unchanged despite national policies. China's pharmaceutical industry is transitioning from a "big pharmaceutical country" to an "innovative pharmaceutical powerhouse," with significant advancements in cutting-edge fields like stem cell and gene therapy [6]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [2] Core Insights - The CXO industry is experiencing a recovery in market conditions, driven by improvements in supply-demand dynamics and a rebound in financing activities for innovative drugs [3][4] - The CDMO sector continues to show high growth potential, with leading companies improving their performance and expanding into emerging markets [5][6] - The CRO sector is approaching a turning point, with signs of demand recovery and improved order conditions [6][7] Summary by Sections CXO Industry Overview - The CXO industry operates on a "water seller" business model, closely tied to the financing of the biopharmaceutical sector. In the first eight months of 2025, overseas innovative drug financing reached $22.6 billion, a year-on-year decline of approximately 36%, while domestic innovative drug financing amounted to $7.75 billion, a year-on-year increase of about 89% [3][31] - The leading companies in the CXO sector are expected to enter an expansion phase as demand recovers, while smaller companies may face increased competition and exit the market [4][44] CDMO Sector - CDMO leading companies have begun to see marginal improvements in performance since Q4 2024, attributed to high overseas revenue and a unique business model that supports project pipeline growth [5][46] - The order situation for CDMO companies has improved significantly, with notable increases in backlogged orders for major players like WuXi AppTec and WuXi Biologics [49][50] - The CDMO business model is characterized by strong customer retention and project scalability, allowing for sustained growth despite challenges in new project signings [52] CRO Sector - The CRO sector is witnessing a divergence in performance among leading companies, with some starting to recover. The overall order situation has shown improvement, indicating a potential demand revival [6][22] - The price increase of experimental monkeys suggests a forthcoming recovery in preclinical CRO demand, highlighting the importance of resource availability for leading CRO companies [6][24] - The integration of AI in drug development processes is expected to enhance efficiency and reduce costs, with many domestic CRO leaders already adopting AI technologies [7][18] Recommended Companies - The report suggests focusing on key players in the CXO sector, including WuXi AppTec, WuXi Biologics, WuXi AppTec, and others, which are positioned well for growth based on their business characteristics and market trends [8][10]

Group 1 - Kanglong Chemical fell by 3.18% [1] - Kelaiying decreased by 3.17% [1] - Zhaoyan New Drug dropped by 2.9% [1] - WuXi AppTec and Medisi both declined over 3% [1]

Group 1 - Fidelity Funds reduced its stake in Zhaoyan New Drug (603127) by 445,700 shares at a price of HKD 24.3867 per share, totaling approximately HKD 10.8692 million [1] - After the reduction, Fidelity Funds holds 7.1303 million shares, representing a holding percentage of 5.99% [1]